The Filings Report

Stryker Corporation

SYKNYSECIK 310764Healthcare / Medical Devicesfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$6.6B
+9.4% on Q2 FY2025
Net income
$1.3B
+44.3% on Q2 FY2025
Free cash flow
$1.1B
+14.1% on Q2 FY2025
Diluted EPS
$3.30
+44.1% on Q2 FY2025
Revenue, TTM
$25.8B
trailing four quarters
Net margin, TTM
14.4%
net income $3.7B
Free cash flow, TTM
$4.7B
$5.5B less $823M capex
Cash and equivalents
$3.4B
long-term debt $14.2B, Jun 30, 2026
Shares, 12-month change
+0.3%
384M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$1.3B
1.2% of market value
Market value
$111.9B
at the close, buybacks

Latest quarter Q2 FY2026, filed July 31, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Stryker Corporation reported revenue of $6.6B, +9.4% on Q2 FY2025, and net income of $1.3B (+44.3%). Operating margin was 25.2%. Free cash flow, operating cash flow less capital expenditures, was $1.1B ($1.3B less $202M). Diluted earnings per share were $3.30.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 31, 2026.

Revenue and net incomeRevenueNet income
$0$2B$4B$6B$8BQ3'22, Revenue: $4.5BQ3'22, Net income: $816MQ3'22Q4'22, Revenue: $5.2BQ4'22, Net income: $563MQ4'22Q1'23, Revenue: $4.8BQ1'23, Net income: $592MQ1'23Q2'23, Revenue: $5.0BQ2'23, Net income: $738MQ2'23Q3'23, Revenue: $4.9BQ3'23, Net income: $692MQ3'23Q4'23, Revenue: $5.8BQ4'23, Net income: $1.1BQ4'23Q1'24, Revenue: $5.2BQ1'24, Net income: $788MQ1'24Q2'24, Revenue: $5.4BQ2'24, Net income: $825MQ2'24Q3'24, Revenue: $5.5BQ3'24, Net income: $834MQ3'24Q4'24, Revenue: $6.4BQ4'24, Net income: $546MQ4'24Q1'25, Revenue: $5.9BQ1'25, Net income: $654MQ1'25Q2'25, Revenue: $6.0BQ2'25, Net income: $884MQ2'25Q3'25, Revenue: $6.1BQ3'25, Net income: $859MQ3'25Q4'25, Revenue: $7.2BQ4'25, Net income: $849MQ4'25Q1'26, Revenue: $6.0BQ1'26, Net income: $745MQ1'26Q2'26, Revenue: $6.6BQ2'26, Net income: $1.3BQ2'26$0$2B$4B$6B$8BQ3'22, Revenue: $4.5BQ3'22, Net income: $816MQ4'22, Revenue: $5.2BQ4'22, Net income: $563MQ4'22Q1'23, Revenue: $4.8BQ1'23, Net income: $592MQ2'23, Revenue: $5.0BQ2'23, Net income: $738MQ2'23Q3'23, Revenue: $4.9BQ3'23, Net income: $692MQ4'23, Revenue: $5.8BQ4'23, Net income: $1.1BQ4'23Q1'24, Revenue: $5.2BQ1'24, Net income: $788MQ2'24, Revenue: $5.4BQ2'24, Net income: $825MQ2'24Q3'24, Revenue: $5.5BQ3'24, Net income: $834MQ4'24, Revenue: $6.4BQ4'24, Net income: $546MQ4'24Q1'25, Revenue: $5.9BQ1'25, Net income: $654MQ2'25, Revenue: $6.0BQ2'25, Net income: $884MQ2'25Q3'25, Revenue: $6.1BQ3'25, Net income: $859MQ4'25, Revenue: $7.2BQ4'25, Net income: $849MQ4'25Q1'26, Revenue: $6.0BQ1'26, Net income: $745MQ2'26, Revenue: $6.6BQ2'26, Net income: $1.3BQ2'26

Net income losses drawn in red.

Free cash flow
$0$500M$1.0B$1.5B$2.0BQ3'22, Free cash flow: $751MQ3'22Q4'22, Free cash flow: $815MQ4'22Q1'23, Free cash flow: $315MQ1'23Q2'23, Free cash flow: $536MQ2'23Q3'23, Free cash flow: $902MQ3'23Q4'23, Free cash flow: $1.4BQ4'23Q1'24, Free cash flow: $37MQ1'24Q2'24, Free cash flow: $481MQ2'24Q3'24, Free cash flow: $1.3BQ3'24Q4'24, Free cash flow: $1.7BQ4'24Q1'25, Free cash flow: $127MQ1'25Q2'25, Free cash flow: $928MQ2'25Q3'25, Free cash flow: $1.4BQ3'25Q4'25, Free cash flow: $1.9BQ4'25Q1'26, Free cash flow: $415MQ1'26Q2'26, Free cash flow: $1.1BQ2'26$0$500M$1.0B$1.5B$2.0BQ3'22, Free cash flow: $751MQ4'22, Free cash flow: $815MQ4'22Q1'23, Free cash flow: $315MQ2'23, Free cash flow: $536MQ2'23Q3'23, Free cash flow: $902MQ4'23, Free cash flow: $1.4BQ4'23Q1'24, Free cash flow: $37MQ2'24, Free cash flow: $481MQ2'24Q3'24, Free cash flow: $1.3BQ4'24, Free cash flow: $1.7BQ4'24Q1'25, Free cash flow: $127MQ2'25, Free cash flow: $928MQ2'25Q3'25, Free cash flow: $1.4BQ4'25, Free cash flow: $1.9BQ4'25Q1'26, Free cash flow: $415MQ2'26, Free cash flow: $1.1BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$5B$10B$15BQ3'22, Cash and equivalents: $1.4BQ3'22, Long-term debt: $12.8BQ3'22Q4'22, Cash and equivalents: $1.8BQ4'22, Long-term debt: $11.9BQ4'22Q1'23, Cash and equivalents: $1.7BQ1'23, Long-term debt: $11.9BQ1'23Q2'23, Cash and equivalents: $1.4BQ2'23, Long-term debt: $11.1BQ2'23Q3'23, Cash and equivalents: $1.9BQ3'23, Long-term debt: $10.4BQ3'23Q4'23, Cash and equivalents: $3.0BQ4'23, Long-term debt: $10.9BQ4'23Q1'24, Cash and equivalents: $2.3BQ1'24, Long-term debt: $10.8BQ1'24Q2'24, Cash and equivalents: $1.9BQ2'24, Long-term debt: $10.1BQ2'24Q3'24, Cash and equivalents: $3.9BQ3'24, Long-term debt: $13.3BQ3'24Q4'24, Cash and equivalents: $3.7BQ4'24, Long-term debt: $12.2BQ4'24Q1'25, Cash and equivalents: $2.3BQ1'25, Long-term debt: $14.4BQ1'25Q2'25, Cash and equivalents: $2.4BQ2'25, Long-term debt: $14.8BQ2'25Q3'25, Cash and equivalents: $3.3BQ3'25, Long-term debt: $14.8BQ3'25Q4'25, Cash and equivalents: $4.0BQ4'25, Long-term debt: $14.9BQ4'25Q1'26, Cash and equivalents: $2.9BQ1'26, Long-term debt: $14.2BQ1'26Q2'26, Cash and equivalents: $3.4BQ2'26, Long-term debt: $14.2BQ2'26$0$5B$10B$15BQ3'22, Cash and equivalents: $1.4BQ3'22, Long-term debt: $12.8BQ4'22, Cash and equivalents: $1.8BQ4'22, Long-term debt: $11.9BQ4'22Q1'23, Cash and equivalents: $1.7BQ1'23, Long-term debt: $11.9BQ2'23, Cash and equivalents: $1.4BQ2'23, Long-term debt: $11.1BQ2'23Q3'23, Cash and equivalents: $1.9BQ3'23, Long-term debt: $10.4BQ4'23, Cash and equivalents: $3.0BQ4'23, Long-term debt: $10.9BQ4'23Q1'24, Cash and equivalents: $2.3BQ1'24, Long-term debt: $10.8BQ2'24, Cash and equivalents: $1.9BQ2'24, Long-term debt: $10.1BQ2'24Q3'24, Cash and equivalents: $3.9BQ3'24, Long-term debt: $13.3BQ4'24, Cash and equivalents: $3.7BQ4'24, Long-term debt: $12.2BQ4'24Q1'25, Cash and equivalents: $2.3BQ1'25, Long-term debt: $14.4BQ2'25, Cash and equivalents: $2.4BQ2'25, Long-term debt: $14.8BQ2'25Q3'25, Cash and equivalents: $3.3BQ3'25, Long-term debt: $14.8BQ4'25, Cash and equivalents: $4.0BQ4'25, Long-term debt: $14.9BQ4'25Q1'26, Cash and equivalents: $2.9BQ1'26, Long-term debt: $14.2BQ2'26, Cash and equivalents: $3.4BQ2'26, Long-term debt: $14.2BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 31, 2026.

Stryker Corporation income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 11, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue6,5896,0207,1716,0576,0225,8666,4365,494+9.4%
Cost of revenue2,0912,2102,5432,2052,1812,1222,2621,977−4.1%
Gross profit4,4983,8104,6283,8523,8413,7444,1743,517+17.1%
Research and development434413401410407405358377+6.6%
Selling, general and administrative2,2292,2812,2272,0452,0792,3002,1231,894+7.2%
Operating income1,6599361,8041,1351,1138375811,085+49.1%
Other income (expense)4662withheldwithheldwithheldwithheld356(42)—
Pretax income1,5648501,7051,0291,0167645281,043+53.9%
Income tax288105856170132110(18)209+118.2%
Net income1,276745849859884654546834+44.3%
Diluted EPS ($)3.301.932.202.222.291.691.412.16+44.1%
Diluted shares (millions)386387—387386386—386—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 31, 2026.

Stryker Corporation balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 11, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents3,3912,8784,0113,2562,3752,3203,6523,850+42.8%
Short-term investments8587898789899184−4.5%
Total current assets14,41813,33814,75513,71113,00313,02214,84714,673+10.9%
Total assets47,93046,29147,84447,05746,33146,00642,97143,833+3.5%
Total current liabilities6,6846,3157,7947,4147,2887,9297,6167,669−8.3%
Long-term debt14,19214,22414,85914,84514,82914,38312,18813,325−4.3%
Total liabilities23,94223,31225,42425,27225,14025,07622,33723,684−4.8%
Stockholders’ equity23,98822,97922,42021,78521,19120,93020,63420,149+13.2%
Shares outstanding (millions)384383383382382382382381—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 31, 2026.

Stryker Corporation cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 11, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow1,2615812,1431,5401,1112501,9311,474+13.5%
Capital expenditures202166268187183123266170+10.4%
Free cash flow (CFO − capex)1,0594151,8751,3539281271,6651,304+14.1%
Depreciation and amortization404397416404387361346371+4.4%
Share repurchases—————————
Dividends paid337337321322321320305305+5.0%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.

Income statement

Stryker Corporation income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 6, 2020FY2018ended Dec 31, 2018filed Feb 7, 2019FY2017ended Dec 31, 2017filed Feb 8, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 12, 2015FY2013ended Dec 31, 2013filed Feb 13, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 13, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Sep 3, 2009FY2007ended Dec 31, 2007filed Feb 26, 2010
Revenue25,11622,59520,49818,44917,10814,35114,88413,60112,44411,3259,9469,6759,0218,6578,3077,3206,7236,7186,001
Cost of revenue9,0518,1557,4406,8716,1405,2945,1884,6634,2643,821—————————
Gross profit16,06514,44013,05811,57810,9689,0579,6968,9388,1807,5046,6026,3566,0195,8765,4965,0344,5394,5874,135
Research and development1,6231,4661,3881,4541,235984971862787715625614536471462394336368375
Selling, general and administrative8,6517,6857,1116,3866,4275,3615,3565,0994,5524,1373,6103,5473,4673,3673,1502,7072,5062,6252,392
Operating income4,8893,6893,8882,8412,5842,2232,7132,5372,2972,1751,8611,2461,2561,7411,6861,7511,5941,5191,307
Other income (expense)232212148(158)(303)(269)(151)(181)(234)(254)(126)(86)(44)(36)34(22)306163
Pretax income4,5143,4923,6732,6832,2811,9542,5622,3562,0631,9211,7351,1601,2121,7051,6861,7291,6241,5801,370
Income tax1,268499508325287355479(1,197)1,043274296645206407341456517432383
Net income3,2462,9933,1652,3581,9941,5992,0833,5531,0201,6471,4395151,0061,2981,3451,2731,1071,1481,017
Diluted EPS ($)8.407.768.256.175.214.205.489.342.684.353.781.342.633.393.453.192.772.782.44
Diluted shares (millions)387386384382382380380380380379381383382383390400399414—

Balance sheet

Stryker Corporation balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 6, 2020FY2018ended Dec 31, 2018filed Feb 7, 2019FY2017ended Dec 31, 2017filed Feb 8, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 12, 2015FY2013ended Dec 31, 2013filed Feb 13, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 13, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Sep 3, 2009FY2007ended Dec 31, 2007filed Feb 26, 2010
Cash and equivalents4,0113,6522,9711,8442,9442,9434,3373,6162,5423,3163,3791,7951,3391,3959051,758659701291
Short-term investments89918284758188————————————
Total current assets14,75514,84712,51810,27510,0179,70711,0589,7337,9937,8617,9438,6848,3358,1487,2077,6325,8514,979—
Total assets47,84442,97139,91236,88434,63134,33030,16727,22922,19720,43516,22317,25815,39913,20612,14610,6589,0717,603—
Total current liabilities7,7947,6167,9216,3034,5495,0414,4004,8073,4853,1483,5024,4612,6571,8761,8401,6051,4411,462—
Long-term debt14,85912,18810,90111,85712,47213,23010,2318,4866,5906,6863,2303,2462,7391,7461,75199618——
Total liabilities25,42422,33721,31920,26819,75421,24617,36015,49912,21710,8857,712————————
Stockholders’ equity22,42020,63418,59316,61614,87713,08412,80711,7309,9809,5508,511————————
Shares outstanding (millions)383382380379378376375373375373373379378381381391398——

Cash flow statement

Stryker Corporation cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 6, 2020FY2018ended Dec 31, 2018filed Feb 7, 2019FY2017ended Dec 31, 2017filed Feb 8, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 12, 2015FY2013ended Dec 31, 2013filed Feb 13, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 13, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Sep 3, 2009FY2007ended Dec 31, 2007filed Feb 26, 2010
Operating cash flow5,0444,2423,7112,6243,2633,2772,1912,6101,5591,9159811,7821,8861,6571,4341,5471,4611,1761,028
Capital expenditures761755575588525487649572598490270233195210226182131155188
Free cash flow (CFO − capex)4,2833,4873,1362,0362,7382,7901,5422,0389611,4257111,5491,6911,4471,2081,3651,3301,021841
Depreciation and amortization1,5701,4261,3411,2781,2721,0761,044966859752590586511486481410385——
Share repurchases————003073002301370010031710862242601,0000
Dividends paid1,2841,2191,1391,05195086377870363656852146240132427923819813690

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$118M
22 sales by 3 insiders; officers and directors $118M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$586M
71 sales by 8 insiders; officers and directors $586M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 24, 2026Wells Preston WendellVP, Chief Financial Officerother109$0.00—3,661Sep 28, 2026
Sep 22, 2026Wells Preston WendellVP, Chief Financial Officerother962$0.00—3,770Sep 24, 2026
Aug 21, 2026Crotty Dylan BramGroup Presidentopen-market saleindirect441$328.61$145K6,102Aug 26, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect40$331.81$13K2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect440$333.18$147K2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect200$333.93$67K2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect80$335.06$27K2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect320$336.79$108K2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect2,308$337.98$780K2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect11,257$338.90$4M2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect10,812$339.71$4M2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect16,612$340.71$6M2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect3,274$341.84$1M2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect3,852$342.80$1M2MAug 20, 2026
Aug 19, 2026Stryker Ronda EDirectoropen-market saleindirect805$343.47$276K2MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect2,239$331.74$743K3MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect2,920$332.69$971K3MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect8,404$333.82$3M3MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect25,536$334.94$9M3MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect131,752$335.64$44M2MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect109,425$336.43$37M2MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect16,243$337.63$5M2MAug 20, 2026
Aug 18, 2026Stryker Ronda EDirectoropen-market saleindirect3,481$338.50$1M2MAug 20, 2026
Aug 18, 2026King DebraSee Remarksopen-market sale826$336.30$278K6,210Aug 18, 2026
Aug 1, 2026Montagnino Kimberly AnnVP, Chief Comm. Officertax withholding155$325.70$50K1,717Aug 4, 2026

Full insider history for Stryker Corporation, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held SYK in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded SYK by quarter.

FundManagerQuarterValueSharesWeightMove
FundsmithTerry SmithQ2 2026$917M3M6.72%trimmed −4.8%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
STRYKER CORP, CIK 310764 on EDGAR
Extract generated
August 27, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: other income FY2025
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues, SalesRevenueNet
Cost of revenue: CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): InvestmentIncomeNonoperating, NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/SYK.json